glp-1/gip/glucagon triple agonist Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Eat Less & Burn More
Description
The FDA still allows GLP-1 prescriptions, but only if you also have at least one qualifying health condition linked to your weight
But medications alone cant address every challenge PMOS brings
While current FDA approvals for semaglutide are limited to diabetes and weight management, the potential cognitive benefits may influence prescribing decisions for at-risk patients
95% CI 0.61, 1.10) [40]
